Skip to main content
Clinical Trials/NCT01125852
NCT01125852
Completed
Not Applicable

Supplementary Angiographic Embolization for Peptic Ulcer Bleeding: A Randomized Controlled Trial

Odense University Hospital1 site in 1 country105 target enrollmentSeptember 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peptic Ulcer Hemorrhage
Sponsor
Odense University Hospital
Enrollment
105
Locations
1
Primary Endpoint
Composite Endpoint
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Peptic ulcer bleeding is a common disorder. Despite optimal endoscopic and medical treatment, there is a high risk of rebleeding and high mortality. In this study the investigators examine whether combined endoscopic haemostasis and angiographic embolization resolves in a better outcome than the traditional use of endoscopic haemostasis alone. The study is a randomised controlled trail.

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
May 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stig Borbjerg Laursen

MD

Odense University Hospital

Eligibility Criteria

Inclusion Criteria

  • Clinical signs of upper GI-bleeding
  • Endoscopic verified high-risk ulcer (Forrest I-IIb)
  • Primary haemostasis achieved

Exclusion Criteria

  • Expected lifetime \< 1 month
  • Upper GI-cancer found at endoscopy

Outcomes

Primary Outcomes

Composite Endpoint

Time Frame: Meassured after a week from primary therapeutic endoscopy

Patients are classified into groups depending on the worst outcome: 1. No clinical signs of rebleeding and requirement of two or less blood transfusions after circulatory stabilization and obtained hemoglobin \> 5,9mmol/L. 2. No clinical signs of rebleeding and requirement of more than two blood transfusions after circulatory stabilization and obtained hemoglobin \> 5,9mmol/L. 3. Rebleeding and achieved secondary haemostasis by endoscopy or angiographic embolization. 4. Rebleeding requiring surgery. 5. Patients who have died. Results are compared using the Wilcoxon rank sum test.

Secondary Outcomes

  • Mortality(1 month)
  • Rebleeding(1 month)
  • Blood transfusion(1 month)
  • Surgical haemostasis(1 month)
  • Endoscopic/other haemostatic retreatment(1 month)
  • Duration of hospitalization(Estimated 4 days)
  • Thromboembolic complications(1 month)

Study Sites (1)

Loading locations...

Similar Trials